Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BioAge Labs, Inc.

BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present at Jefferies London Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Announces Pricing of Upsized Initial Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging
From BioAge Labs, Inc.
Via Business Wire
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways at Upcoming International Conferences
From BioAge Labs, Inc.
Via Business Wire
BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans
From BioAge Labs, Inc.
Via Business Wire
BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences
From BioAge Labs, Inc.
Via Business Wire
BioAge Partners With Age Labs to Decipher Healthy Longevity Using Samples and Data From a Preeminent Northern European Biobank
From BioAge Labs, Inc.
Via Business Wire
BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference: “Targeting Aging Pathways to Treat Chronic Disease” — June 14, 2022, 11 AM
From BioAge Labs, Inc.
Via Business Wire
BioAge Chief Business Officer Peng Leong Appointed Company’s First Head of Brain Aging
From BioAge Labs, Inc.
Via Business Wire
BioAge Developing a Novel Class of Potent NLRP3 Inhibitors With Distinct Structural and Pharmacologic Properties for Inflammatory and Age-Related Diseases
From BioAge Labs, Inc.
Via Business Wire
BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
From BioAge Labs, Inc.
Via Business Wire
Nature Paper: BioAge’s Oral Drug Targeting the Aging Immune System Prevents Death From COVID-19 in Aged Mice
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs to Participate in Truist Symposium on AI-driven Drug Discovery, Multiple Upcoming Biotech Investment Conferences
From BioAge Labs, Inc.
Via Business Wire
BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer
From BioAge Labs, Inc.
Via Business Wire
BioAge Appoints Rekha Hemrajani and Jason Coloma to its Board of Directors
From BioAge Labs, Inc.
Via Business Wire
BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen’s Phase 1 APJ Agonist To Treat Diseases of Aging
From BioAge Labs, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.